CD34 and acute kidney injury: Suzuki et al. recently documented the first human case in a phase I/II clinical trial involving the transplantation of autologous granulocyte colony-stimulating factor-mobilized peripheral blood CD34-positive cells for the treatment of severe acute kidney injury (Suzuki et al., 2021).